Authors/Disclosures
|
Philip De Jager, MD, PhD
(Columbia University Irving Medical Center)
|
Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. De Jager has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Puretech. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. The institution of Dr. De Jager has received research support from roche. The institution of Dr. De Jager has received research support from Biogen. The institution of Dr. De Jager has received research support from puretech. |
|
Ali Ezzati, MD
(University of California, Irvine)
|
Dr. Ezzati has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mist Research. Dr. Ezzati has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BioDelivery Sciences International (BDSI) . The institution of Dr. Ezzati has received research support from NIA. The institution of Dr. Ezzati has received research support from Alzheimer's Association. The institution of Dr. Ezzati has received research support from Cure Alzheimer's Fund. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Rupert Sandbrink, MD, PhD
(LiSciCon)
|
Dr. Sandbrink has received personal compensation for serving as an employee of Topas Therapeutics. Dr. Sandbrink has received personal compensation for serving as an employee of Vico Therapeutics. Dr. Sandbrink has received stock or an ownership interest from Forward Pharma. Dr. Sandbrink has received stock or an ownership interest from Topas Therapeutics. Dr. Sandbrink has received stock or an ownership interest from Vico Therapeutics. Dr. Sandbrink has received stock or an ownership interest from Bayer. |
|
Christoph Pohl, MD
|
No disclosure on file |
|
|
No disclosure on file |
|
David A. Hafler, MD, FAAN
(Yale University School of Medicine, Dept of Neurology)
|
Dr. Hafler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Hafler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genetech. Dr. Hafler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Hafler has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Joint Commission International. |